Background In the absence of targetable mutations or immune checkpoints, cisplatin-
doublet chemotherapy remains the standard of care in non-small cell lung cancer (NSCLC) …

Non-small cell lung carcinomas (NSCLC) account for about 80% of lung cancers and their
remarkable heterogeneity manifests in histology, pathogenesis, prognosis, and response to …

Background/Aims: Drug resistance remains a main obstacle to the treatment of non-small
cell lung cancer (NSCLC). The aim of this study was to identify the expression profiles of …

Background The average five-year survival for non-small cell lung cancer (NSCLC) patients
is approximately 15%. Emerging evidence indicates that microRNAs (miRNAs) constitute a …

Lung Cancer, the second most common cancer worldwide, remains the leading cause of
cancer-related deaths, contemporarily. More than 85% of identified lung cancer cases are …

Lung cancer remains the leading cause of cancer-related death worldwide for both men and
women, and non-small cell lung cancer (NSCLC) accounts for approximately 80% of all …

Emerging studies demonstrated that miRNAs played fundamental roles in lung cancer. In
this study, we attempted to explore the clinical significance of the miRNA signature in …

With more than 80% of all diagnosed lung cancer cases, non-small cell lung cancer
(NSCLC) remains the leading cause of cancer death worldwide. Exact diagnosis is mostly …

Objective: To identify new molecular diagnostic markers for non-small cell lung carcinoma
(NSCLC) by analyzing microRNA (miRNA) expression profile differences in samples from …

Non-small cell lung cancer (NSCLC) is the leading cause of cancer death. Systematically
characterizing miRNAs in NSCLC will help develop biomarkers for its diagnosis and …